JP2024520900A5 - - Google Patents
Info
- Publication number
- JP2024520900A5 JP2024520900A5 JP2023569788A JP2023569788A JP2024520900A5 JP 2024520900 A5 JP2024520900 A5 JP 2024520900A5 JP 2023569788 A JP2023569788 A JP 2023569788A JP 2023569788 A JP2023569788 A JP 2023569788A JP 2024520900 A5 JP2024520900 A5 JP 2024520900A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- combination
- cancer
- leukemia
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163187753P | 2021-05-12 | 2021-05-12 | |
| US63/187,753 | 2021-05-12 | ||
| PCT/US2022/029002 WO2022241122A1 (en) | 2021-05-12 | 2022-05-12 | Combinations for treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520900A JP2024520900A (ja) | 2024-05-27 |
| JP2024520900A5 true JP2024520900A5 (https=) | 2025-05-19 |
Family
ID=84028869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023569788A Pending JP2024520900A (ja) | 2021-05-12 | 2022-05-12 | 癌の治療のための組合せ |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240238291A1 (https=) |
| EP (1) | EP4337329A4 (https=) |
| JP (1) | JP2024520900A (https=) |
| KR (1) | KR20240006625A (https=) |
| CN (1) | CN117425495A (https=) |
| AU (1) | AU2022271791A1 (https=) |
| CA (1) | CA3214990A1 (https=) |
| WO (1) | WO2022241122A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017214367A1 (en) | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| TW202525813A (zh) | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
| EP4132932A4 (en) | 2020-04-07 | 2024-04-17 | Syndax Pharmaceuticals, Inc. | COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOF |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
| EP4626426A1 (en) * | 2022-11-30 | 2025-10-08 | JANSSEN Pharmaceutica NV | Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent |
| WO2024114666A1 (en) * | 2022-11-30 | 2024-06-06 | Janssen Pharmaceutica Nv | Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor |
| TW202517650A (zh) * | 2023-07-17 | 2025-05-01 | 美商庫拉腫瘤技術股份有限公司 | 包含ｍｅｎｉｎ抑制劑之醫藥組合物 |
| IL325861A (en) | 2023-07-17 | 2026-03-01 | Kura Oncology Inc | Crystalline forms of menin inhibitor |
| WO2025082444A2 (en) * | 2023-10-20 | 2025-04-24 | Janssen Pharmaceutica Nv | (r) -n-ethyl-5-fluoro-n-isopropyl-2- ( (5- (2- (6- ( (2-methoxyethyl) (methyl) amino) -2-methylhexan-3-yl) -2, 6-diazaspiro [3.4] octan-6-yl) -1, 2, 4-triazin-6-yl) oxy) benzamide, formulations and dosage regimens thereof, for use in treating cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10869868B2 (en) * | 2016-01-26 | 2020-12-22 | Memorial Sloan Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia |
| JP6991585B2 (ja) * | 2016-05-02 | 2022-01-12 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | メニン阻害剤としてのピペリジン |
-
2022
- 2022-05-12 US US18/560,282 patent/US20240238291A1/en active Pending
- 2022-05-12 JP JP2023569788A patent/JP2024520900A/ja active Pending
- 2022-05-12 AU AU2022271791A patent/AU2022271791A1/en active Pending
- 2022-05-12 KR KR1020237042364A patent/KR20240006625A/ko active Pending
- 2022-05-12 CN CN202280034693.9A patent/CN117425495A/zh active Pending
- 2022-05-12 EP EP22808351.5A patent/EP4337329A4/en active Pending
- 2022-05-12 WO PCT/US2022/029002 patent/WO2022241122A1/en not_active Ceased
- 2022-05-12 CA CA3214990A patent/CA3214990A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024520900A5 (https=) | ||
| JP5416328B2 (ja) | 血管形成及び／又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体ｚｄ６４７４の使用 | |
| EP3066101B1 (en) | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors | |
| CN103282037B (zh) | 抗肿瘤生物碱的联合治疗 | |
| KR20220024639A (ko) | 백혈병 또는 골수이형성 증후군을 치료하기 위한 베네토클락스, 길테리티닙, 미도스타우린 또는 다른 화합물과 조합된 아자시티딘 | |
| US20050209186A1 (en) | Method for treating chronic myelogenous leukemia | |
| JP2020505433A5 (https=) | ||
| JP2020535173A5 (https=) | ||
| EA037152B1 (ru) | Способ лечения рака | |
| JP2018177808A (ja) | 抗癌療法 | |
| JP2024516795A5 (https=) | ||
| EP2177223B1 (en) | Homoharringtonine alone or combined with other agents for use in treating chronic myelogenous leukemia resistant or intolerant to protein kinase inhibitors other than STI 571 | |
| Martinez et al. | A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphoblastic leukemia. | |
| CN100409895C (zh) | 用于治疗白血病和淋巴瘤的阿普立定组合 | |
| JP2009536956A (ja) | 抗癌治療法 | |
| Belani et al. | Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group | |
| US12023334B2 (en) | Composition including rilpivirine and method for treating tumors or cancer | |
| JP2021063014A (ja) | 白血病治療薬 | |
| Ogata et al. | Dosage escalation study of S-1 and irinotecan in metronomic chemotherapy against advanced colorectal cancer | |
| JP2023548303A5 (https=) | ||
| US8198264B2 (en) | Method for treating head and neck cancer | |
| Serrano et al. | Chemotherapy with gemcitabine in advanced biliary tract carcinoma | |
| Ogawa et al. | Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma | |
| Khafif et al. | Results of phase I-II trial of concomitant hyperfractionated radiation and oral etoposide (VP-16) in patients with unresectable squamous cell carcinoma of the head and neck | |
| CN115581703A (zh) | 复方吉西他滨组合物及应用 |